Results of the ELISA II trial

September 06, 2005


Aspirin and Clopidogrel are widely used and proven to be effective in the treatment of an acute coronary syndrome (ACS). High-risk patients with non-ST segment elevation acute coronary syndrome ACS (NSTE ACS) benefit from the addition of glycoprotein (GP) IIb/IIIa inhibitor. In low-risk patients undergoing elective percutanous coronary intervention (PCI), receiving Aspirin and high dose (600 mg) Clpoidogrel, the addition of a GP IIb/IIIa inhibitor (Abciximab) had no additional beneficial effect. However, no study has been performed examining the value of IIb/IIIa inhibitor in patients with NSTE ACS undergoing PCI. The ELISA II trial was designed to compare dual antiplatelet (AP) (Aspirin and Clopidogrel 600 mg) with Triple AP (Aspirin, Clopidogrel 300 mg and Tirofiban, a GP IIb/IIIa inhibitor) in patients with NSTE ACS, undergoing coronary angiography.


A total of 328 patients with NST ACS were Included. The primary end point was enzymatic infarct size (measured by Cumulative LDH release under the curve and Peak Creatinin Kinase) and the secondary end point was the epicardial coronary artery flow (TIMI flow) at initial angigoram of the culprit vessel. The patients were randomised to pre-treatment with dual (N=166, Aspirin, Clopidogrel (600 mg)) or triple AP therapy (N=162, Aspirin, Clopidogrel (300 mg) and Tirofiban.


No differences in baseline characteristics were present. Coronary angiography was performed in 98% of the patients. Enzymatic infarct size could be assessed in 89% of pts. No significant difference in infarct size was found between the groups. Initial TIMI 3 flow of the culprit lesion was significantly more often present in patients who received triple AP therapy (67% vs. 47%, p=0.001). There was a strong trend toward better event (myocardial infarction and death) free survival both at 96 hours and 30 days after randomization in the triple AP group.


The ELISA II trial shows that in patients with NSTE ACS, triple AP pre-treatment tended to decrease enzymatic infarct size and was associated with a significantly better perfusion of the culprit vessel at initial angiography. Enzymatic infarct size was smaller than expected and therefore a larger trial might be needed to evaluate whether the observed difference in infarct size is real or based on chance.

European Society of Cardiology

Related Aspirin Articles from Brightsurf:

An aspirin a day keeps the bowel doctor away
A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed.

What are the risks and benefits of low-dose aspirin?
Low-dose aspirin significantly lowers cardiovascular disease risk but increases the risk of bleeding, according to a review published in the British Journal of Clinical Pharmacology.

Benefit seen for ticagrelor alone, without aspirin, in patients with ACS
The research was presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Study: An aspirin a day does not keep dementia at bay
Taking a low-dose aspirin once a day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or probable Alzheimer's disease, nor does it slow the rate of cognitive decline, according to a large study published in the March 25, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.

Aspirin's health benefits under scrutiny
Taking a baby aspirin every day to prevent a heart attack or stroke should no longer be recommended to patients who haven't already experienced one of these events.

Aspirin may no longer be effective as cardiovascular treatment
A new paper in Family Practice, published by Oxford University Press, found that the widespread use of statins and cancer screening technology may have altered the benefits of aspirin use.

Migraine headaches? Consider aspirin for treatment and prevention
Evidence from 13 randomized trials of the treatment of migraine in 4,222 patients and tens of thousands of patients in prevention of recurrent attacks supports the use of high dose aspirin from 900 to 1,300 milligrams to treat acute migraine as well as low dose daily aspirin from 81 to 325 milligrams to prevent recurrent attacks.

Aspirin use after biliary tract cancer diagnosis
Researchers in this observational study examined if aspirin use after a diagnosis of a biliary tract cancer, which includes gallbladder cancer, was associated with reduced risk of death among nearly 3,000 patients.

Aspirin may prevent air pollution harms
A new study is the first to report evidence that nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin may lessen the adverse effects of air pollution exposure on lung function.

Aspirin should not be recommended for healthy people over 70
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk of cardiovascular disease.

Read More: Aspirin News and Aspirin Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to